New Drugs and Clinical Trials · eu
Talvey combination therapy gains EU committee backing, potentially moving earlier in relapsed myeloma treatment
A phase 3 trial showed that talquetamab combined with daratumumab can delay disease progression and improve overall survival. The regimen has moved a step closer to second-line use, but European Commission approval is still pending, and risks of infection and immune reactions must also be considered.
For patients with multiple myeloma, regaining disease control after the first relapse is a critical point in treatment. Johnson & Johnson announced on October 16 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended expanding the indication for Talvey (talquetamab), supporting its use with daratumumab, with or without pomalidomide, in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The opinion moves the regimen closer to second-line use, but final approval from the European Commission is still required.
The combination attacks myeloma cells from different directions. Talquetamab is a bispecific antibody: one end recognizes GPRC5D on myeloma cells, while the other binds to CD3 on T cells, bringing immune cells toward cancer cells. Daratumumab targets CD38. The rationale for combining the two is to achieve deeper, longer-lasting disease control through different targets and immune mechanisms.
The key evidence supporting this recommendation comes from the randomized phase 3 MonumenTAL-3 trial. The study enrolled 864 patients previously treated with lenalidomide and a proteasome inhibitor. It compared a two-drug regimen of talquetamab and daratumumab, a three-drug regimen adding pomalidomide, and a control regimen of daratumumab, pomalidomide, and dexamethasone. The results were presented on June 13 at the European Hematology Association annual meeting and simultaneously published in The New England Journal of Medicine. The latest development is that these data have now gained regulatory committee backing.
At a median follow-up of 24.6 months, the hazard ratios for disease progression or death with the talquetamab-containing three-drug and two-drug regimens versus the control group were 0.28 and 0.33, respectively, equivalent to relative risk reductions of 72% and 67% during follow-up. At 24 months of treatment, the proportions of patients alive without disease progression were 81.3% and 77.6%, respectively, compared with 51.2% in the control group. These figures reflect the regimens’ ability to delay disease progression; they do not mean the disease has been cured.
Overall survival also improved: at 24 months, survival rates were 89.2% in the three-drug group and 87.9% in the two-drug group, compared with 79.1% in the control group. However, the trial is ongoing, and the current results come from a planned interim analysis. Further follow-up is needed to determine whether longer-term survival and disease control can be sustained. Both experimental groups outperformed the same control group, but the percentages alone cannot establish that adding pomalidomide is necessarily better.
Beyond efficacy, the treatment burden is also clear. Rates of grade 3 or 4 infections in the three-drug, two-drug, and control groups were 37.7%, 29.2%, and 42.2%, respectively. Although the rate was lower in the two-drug group, nearly 30% of patients still experienced these infections. Trial data compiled by the International Myeloma Foundation also showed that cytokine release syndrome occurred in 67.8% of patients in the three-drug group and 58.4% in the two-drug group, with most cases being grade 1 or 2. This indicates that activating T cells to fight cancer also requires managing reactions caused by immune activation.
The population studied places another limit on how the results should be interpreted. According to OncLive’s summary, the trial excluded patients whose disease was already refractory to anti-CD38 antibody therapy, so the same benefits cannot be directly assumed for all patients with relapsed disease. If approved by the European Commission, the combination will add an option at an earlier stage of relapse. Its actual place in treatment will still need to be determined by considering patients’ prior therapies, treatment resistance, and the side effects they can tolerate.